Physician profile
Robert S Kaufmann
NPI 1376573147
$18,506.14
in general payments reported to CMS, 2019-2025
73 companies · $18.70 in 2025
The $18.70 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,915 · 2020: $6,760 · 2021: $2,413 · 2022: $3,995 · 2023: $2,218 · 2024: $1,187 · 2025: $18.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,423.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $5,011.49 | 2019-2020 | |
| Novo Nordisk INC | $2,784.94 | 2019-2024 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,389.06 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $963.86 | 2019-2024 | Farxiga, Breztri |
| Amgen INC. | $912.73 | 2019-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $776.99 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $571.93 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $463.14 | 2020-2023 | |
| Abbott Laboratories | $452.78 | 2020-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $440.82 | 2019-2024 | Mounjaro, Jardiance, Trulicity |
| Kowa Pharmaceuticals America, INC. | $363.26 | 2020-2022 | |
| Pfizer INC. | $355.38 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.10 | 2019-2024 | Synjardy, Jardiance, Ofev |
| Gilead Sciences, INC. | $260.84 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $229.60 | 2021-2024 |
Show all 72 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kaufmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.